Skip to main content

Table 4 Multivariate analyses of factors associated with recurrence-free survival (RFS) in GIST patients with adjuvant imatinib therapy (*, P < 0.05)

From: Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome

Variable

RFS hazard ratio (95% Cl)

Pvalue

Tumor size (≤10, > 10 cm)

0.801 (0.222-2.889)

0.736

Mitosis count (≤10, > 10/50 HPF)

1.944 (0.546-6.913)

0.307

Serosal invasion (Yes, No)

3.549 (1.047-12.025)

0.043*

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us